

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

GRÜNENTHAL GMBH,

Petitioner

v.

ANTECIP BIOVENTURES II LLC,

Patent Owner

---

Case PGR2017-00008

U.S. Patent No. 9,283,239

---

**PATENT OWNER'S RESPONSE**

***Mail Stop "PATENT BOARD"***

Patent Trial and Appeal Board

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

**TABLE OF CONTENTS**

	<b><u>Page</u></b>
I. INTRODUCTION .....	1
II. A PERSON SKILLED IN THE ART .....	2
III. PETITIONER MUST CARRY ITS BURDEN, IF AT ALL, IN ITS PETITION. ....	3
IV. PETITIONER HAS NOT SHOWN BY A PREPONDERANCE OF THE EVIDENCE THAT THE CLAIMS OF THE '239 PATENT LACK WRITTEN DESCRIPTION SUPPORT.....	9
A. The written description inquiry asks whether the disclosure conveys to those skilled in the art that the inventor had possession of the claimed subject matter. ....	11
B. Written description support exists for the dosage range about 80 mg to about 500 mg over a six-month period. ....	13
1. The dosage range about 80 mg to about 500 mg within a six- month period is expressly disclosed at column 10, lines 47 and 60–62, and in combination with column 13, lines 27–33. ....	13
2. The dosage range about 80 mg to about 500 mg within a six month period is expressly disclosed at column 10, lines 46-62. ....	16
3. The dosage range of about 80 mg to about 500 mg over six months is also repeatedly disclosed in the specification by what appear to be nominally variant ranges, based on the use of the term “about”. ....	17
4. Contrary to petitioner’s argument, Example 3 also provides explicit support in the specification for the use of	

the overall dosage range about 80 mg to about 500 mg to treat CRPS.....23

5. The disclosure’s repeated identification of 80 mg as a lower limit and 500 mg as an upper limit would cause a POSA to recognize that the patentee was in possession of the claimed dosage range administered over a six month period.....27

C. The claimed six-month period for a dosage range is expressly disclosed by the ‘239 specification, and additional emphasis is unnecessary because a POSA would have understood to use a six-month period when administering oral zoledronic acid.....34

V. CONCLUSION.....37

**TABLE OF AUTHORITIES**

	<b>Page(s)</b>
<b>Cases</b>	
<i>Alcon Research Ltd. v. Barr Labs., Inc.</i> , 745 F.3d 1180 (Fed. Cir. 2014) .....	12
<i>Ariad Pharm., Inc. v. Eli Lilly &amp; Co.</i> , 598 F.3d 1336 (Fed. Cir. 2010) (en banc) .....	12
<i>Blue Calypso, LLC v. Groupon, Inc.</i> , 815 F.3d 1331 (Fed. Cir. 2016) .....	11
<i>Cohesive Techs., Inc. v. Waters Corp.</i> , 543 F.3d 1351 (Fed. Cir. 2008) .....	20
<i>Crown Packaging Tech., Inc. v. Ball Metal Bev. Container Corp.</i> , 635 F.3d 1373 (Fed. Cir. 2011) .....	29
<i>Dynamic Drinkware, LLC v. Nat'l Graphics, Inc.</i> , 800 F.3d 1375 (Fed. Cir. 2015) .....	8
<i>Ex Parte Juan Mantelle</i> , Appeal No. 2015-004605, 2017 WL 2200409 (PTAB 2017) .....	12
<i>Ex Parte Jung-Sheng Wu and Raghunath Padiyatgh</i> , 110 U.S.P.Q. 561 (PTAB 2016) .....	12
<i>In re Magnum Oil Tools Int'l, Ltd.</i> , 829 F.3d 1364 (Fed. Cir. 2016) .....	5, 6, 7, 8
<i>Purdue Pharma L.P. v. Faulding Inc.</i> , 230 F.3d 1320 (Fed. Cir. 2000) .....	9, 10, 15
<i>Union Oil Co. of California v. A. Richfield Co.</i> , 208 F.3d 989 (Fed. Cir. 2000) .....	15, 33
<i>Vas-Cath Inc. v. Mahurkar</i> , 935 F.2d 1555 (Fed. Cir. 1991) .....	12

*In re Wertheim*,  
541 F.2d 257, 191 U.S.P.Q. 90 (C.C.P.A 1976).....14, 30, 33

### Statutes

35 U.S.C. § 312(a)(3).....5

35 U.S.C. § 316(e) .....4, 7

35 U.S.C. § 322(a)(3).....4, 5

35 U.S.C. § 326(e) .....4

### Other Authorities

37 C.F.R. § 42.6 .....39

37 C.F.R. § 42.23(b) .....4, 5

37 C.F.R. § 42.24(d) .....40

37 C.F.R. § 42.220 .....39

U.S. Patent No. 8,802,658.....25

U.S. Patent No. 9,283,239.....*passim*

U.S. Patent Application Publ'n No. US 2013/0404488 A1 (published  
Nov. 14, 2013) .....1

U.S. Patent Application Publ'n No. US 2014/0051669 A1 (published  
Feb. 20, 2014) .....2

Dave H. Schweitzer et al., *Improved Treatment of Paget's Disease  
with Dimethylaminohydroxypropylidene Bisphosphonate* .....35

THEODORE L. BROWN ET AL., *CHEMISTRY, THE CENTRAL SCIENCE*  
(10th ed. 2006.) .....20

Ian R. Reid et al., *Intravenous Zoledronic Acid In Postmenopausal  
Women With Low Bone Mineral Density*.....36

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.